A feasibility study on the development of Asacor for emergency use to reduce the risk of vascular mortality in patients with suspected AMI

Asamedic AS, a Norwegian biotech company, is developing Asacor, which is an innovative, soluble formulation of acetylsalicylic acid (ASA), i.e. a drug which is supposed to reduce the risk of vascular mortality in patients with a suspected acute myocardial infarction (AMI). Asacor consists of a double chamber system in which the ASA 300 mg powder contained in an inner chamber falls into the solvent present in the outer chamber after activation of the system. The active substance ASA 300 mg dissolves within 30 sec after the patient or their caregiver shakes the container. The solution thus obtained This oral drinking formulation can be taken directly by patients with a suspected AMI at home or in transit, and should enable the thrombocyte aggregation inhibiting effect to occur as quickly as possible. This will again result in marked platelet thromboxane B2 (TxB2) suppression by the time of arrival at the hospital and initial medical assessment. The objective of the FeAsacor feasibility project is to deliver a comprehensive feasibility analysis of the development of Asacor as a medicinal product for the global market. The feasibility analysis will include a thorough assessment of technical, market access, regulatory and financing feasibility including a risk analysis and risk mitigation plan. Of particular importance are the analysis of business model with associated funding needs and financing options; of price sensitivity in the various non-benchmark markets and its consequences for overall sales volumes and indirectly for any term sheets with commercial partners; and technically wise in terms of pharmacokinetic and –dynamic clinical data.